Gentamicin monitoring in neonates. 1988

G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
Département de Pharmacologie Clinique, Hôpital Saint-Vincent de Paul, Paris, France.

The elimination of gentamicin (G) was studied in 103 neonates (30 premature) during the first month of life after 2.5 mg/kg i.v. (as infusion) over 20-30 min. G plasma levels, measured by EMIT assay, were obtained before and at 1, 2, 3, and 6 h after infusion. We derived individual first-order kinetic parameters and designed optimal dose regimens. G plasma clearance, half-life, and recommended dose (mg/kg/h) changed exponentially with postnatal age during the first 14 days of life. No significant changes in kinetic values were noted during the first 3 days of life; however, they varied linearly with gestational age when they were measured during this period. Apgar score at 10 min and blood urea nitrogen significantly influenced the same parameters. The predictive value of a designed dose regimen was evaluated at steady-state, after dosage adjustment using two plasma concentration values: the minimum plasma concentration was below 2 mg/L in 93% of the patients; the plasma concentration observed within 1 h after completion of the infusion was (mean +/- SD) 5.33 +/- 0.97 mg/L. Our data suggest that 2.5 mg/kg every 12 h is appropriate in most neonates except for 0-2-day-old premature infants who require 2.5 mg/kg every 18 h. Monitoring of G plasma levels is advisable in infants with low Apgar score and/or renal failure.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D007236 Infant, Small for Gestational Age An infant having a birth weight lower than expected for its gestational age.
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
January 2003, Acta medica portuguesa,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
September 2016, Archives of disease in childhood,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
January 2001, Medycyna wieku rozwojowego,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
January 1984, Developmental pharmacology and therapeutics,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
October 1996, Therapeutic drug monitoring,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
January 2024, Journal of neonatal-perinatal medicine,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
April 1995, The Annals of pharmacotherapy,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
August 2016, Antimicrobial agents and chemotherapy,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
September 2000, The Pediatric infectious disease journal,
G Pons, and P d'Athis, and E Rey, and D de Lauture, and M O Richard, and J Badoual, and G Olive
December 1998, The Pediatric infectious disease journal,
Copied contents to your clipboard!